TY - JOUR
T1 - INTER-HEART
T2 - A global study of risk factors for acute myocardial infarction
AU - INTER-HEART Investigators
AU - Ôunpuu, Stephanie
AU - Negassa, Abdissa
AU - Yusuf, Salim
N1 - Funding Information:
Argentina: INCLEN, OASIS-4; Australia/New Zealand: OASIS-4; Botswana: Astra South Africa; Brazil: OASIS-4; Cameroon: INCLEN; Canada: OASIS-4; Chile: INCLEN, Universidad de la Frontera, Sociedad Chilena de Cardiologia Filial Sur; Colombia: Colciencias, Ministerio de Salud; Croatia: Croatian Ministry of Science and Technology; Czech Republic: OASIS-4; Germany: OASIS-4; Greece: OASIS-4; Hungary: ASTRA Hassle, National Health Science Council, OASIS-4; Iran: Iran Ministry of Health; Italy: OASIS-4; Japan: Sankyo Pharmaceutical Co, Merck Japan, Astra Japan; Kuwait: Endowment Fund for Health Development in Kuwait; INCLEN; Netherlands: OASIS-4; Pakistan: ATCO Laboratories; Philippines: Philippine Council for Health Research and Development, INCLEN, Pfizer Philippines Foundation, Inc, Astra Pharmaceuticals (Philippines), Inc, Astra Fund for Clinical Research and Continuing Medical Education, Pharmacia and Upjohn Inc; Poland: OASIS-4; Singapore: Singapore National Heart Association; South Africa: MRC South Africa, Parke-Davis Pharmaceuticals, Aventis, OASIS-4; Spain: OASIS-4; Sweden: Swedish Heart and Lung Foundation Grant from the Swedish State under LUA Agreement; Thailand: INCLEN, The Heart Association, Thailand Research Fund; United States: OASIS-4; Zimbabwe: INCLEN.
Funding Information:
INTER-HEART is sponsored by the World Health Organization and the World Heart Federation and has received funds from the Canadian Institute of Health Research, Heart and Stroke Foundation of Ontario, the International Clinical Epidemiology Network, and 8 pharmaceutical companies. For the majority of countries, national coordinators have raised funds to cover patient costs and costs of local coordination (Appendix B). Most have secured at least one funding source and have approached multiple additional sources.
Funding Information:
The INTER-HEART study is funded through unrestricted grants from several pharmaceutical companies (with major contributions from Astra Zeneca, Novartis, Hoechst Marion Roussel, Knoll Pharmaceuticals, Bristol-Myers Squibb, and Sanofi-Sythelabo), the International Clinical Epidemiology Network, Canadian Institutes of Health Research, Heart and Stroke Foundation of Ontario, and various national bodies in different countries.
PY - 2001
Y1 - 2001
N2 - Background: Although declines in mortality rates have occurred in most developed countries, increases are being seen in developing countries. Our knowledge of risk factors for acute myocardial infarction (AMI) is largely derived from studies in the former. Applicability of these results to other populations is unknown. The objectives of INTER-HEART are to determine the association between risk factors and AMI within populations defined by ethnicity and/or geographic region and to assess the relative importance of risk factors across these populations. Methods: INTER-HEART is a study of 14,000 cases of AMI and 16,000 matched control patients from 46 countries, which was conducted with a standardized protocol. Questionnaires were translated into 11 languages; physical measurements were obtained, and 20 mL of blood was drawn and shipped frozen to a central laboratory in Canada. The study will evaluate the importance of conventional and emerging risk factors within each geographic region and whether their impact varies by region. Results: INTER-HEART is sponsored by the World Health Organization and the World Heart Federation and has received funding from several peer-reviewed agencies and many different pharmaceutical companies. A vanguard phase (February 1999 to 2000) enrolled 4000 subjects from 41 countries. Full data collection started in April 2000 and is expected to be completed by October 2002. Conclusions: Several years of targeted work have allowed the development of the concepts that were tested in the pilot studies. This has ensured the feasibility of INTER-HEART. This study has the potential to have a major impact in developing a worldwide strategy for cardiovascular disease prevention, especially in developing countries and nonwhite populations.
AB - Background: Although declines in mortality rates have occurred in most developed countries, increases are being seen in developing countries. Our knowledge of risk factors for acute myocardial infarction (AMI) is largely derived from studies in the former. Applicability of these results to other populations is unknown. The objectives of INTER-HEART are to determine the association between risk factors and AMI within populations defined by ethnicity and/or geographic region and to assess the relative importance of risk factors across these populations. Methods: INTER-HEART is a study of 14,000 cases of AMI and 16,000 matched control patients from 46 countries, which was conducted with a standardized protocol. Questionnaires were translated into 11 languages; physical measurements were obtained, and 20 mL of blood was drawn and shipped frozen to a central laboratory in Canada. The study will evaluate the importance of conventional and emerging risk factors within each geographic region and whether their impact varies by region. Results: INTER-HEART is sponsored by the World Health Organization and the World Heart Federation and has received funding from several peer-reviewed agencies and many different pharmaceutical companies. A vanguard phase (February 1999 to 2000) enrolled 4000 subjects from 41 countries. Full data collection started in April 2000 and is expected to be completed by October 2002. Conclusions: Several years of targeted work have allowed the development of the concepts that were tested in the pilot studies. This has ensured the feasibility of INTER-HEART. This study has the potential to have a major impact in developing a worldwide strategy for cardiovascular disease prevention, especially in developing countries and nonwhite populations.
UR - http://www.scopus.com/inward/record.url?scp=0035028919&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0035028919&partnerID=8YFLogxK
U2 - 10.1067/mhj.2001.114974
DO - 10.1067/mhj.2001.114974
M3 - Article
C2 - 11320357
AN - SCOPUS:0035028919
SN - 0002-8703
VL - 141
SP - 711
EP - 721
JO - American Heart Journal
JF - American Heart Journal
IS - 5
ER -